Immunocore Files 8-K on Security Holder Vote
Ticker: IMCR · Form: 8-K · Filed: May 23, 2024 · CIK: 1671927
| Field | Detail |
|---|---|
| Company | Immunocore Holdings PLC (IMCR) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: IMCR
TL;DR
IMCR filed an 8-K for a shareholder vote - details TBD.
AI Summary
Immunocore Holdings plc filed an 8-K on May 23, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the vote's subject matter or outcomes, but it formally documents the process as required by SEC regulations.
Why It Matters
This filing indicates that Immunocore is engaging its shareholders on important corporate matters, a standard procedure for publicly traded companies that can signal upcoming strategic decisions or governance changes.
Risk Assessment
Risk Level: low — This is a routine procedural filing with no immediate financial or operational impact disclosed.
Key Players & Entities
- Immunocore Holdings plc (company) — Registrant
- May 23, 2024 (date) — Date of Report
FAQ
What specific matters were submitted for a vote by Immunocore's security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When did the vote take place or when is it scheduled?
The filing was made on May 23, 2024, and indicates the submission of matters as of that date, but does not specify the voting period.
What is the significance of this 8-K filing for Immunocore's shareholders?
It formally documents that the company has submitted items for shareholder consideration and voting, a necessary step in corporate governance.
Are there any financial implications mentioned in this filing?
No specific financial amounts or implications are detailed in this particular 8-K filing.
Where can shareholders find more information about the matters voted upon?
Further details regarding the specific matters voted upon would typically be found in proxy statements or other related filings that precede or accompany this 8-K.
Filing Stats: 1,055 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-05-23 16:50:35
Filing Documents
- ef20029907_8k.htm (8-K) — 64KB
- 0001140361-24-027312.txt ( ) — 202KB
- imcr-20240523.xsd (EX-101.SCH) — 4KB
- imcr-20240523_lab.xml (EX-101.LAB) — 21KB
- imcr-20240523_pre.xml (EX-101.PRE) — 16KB
- ef20029907_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 23, 2024, Immunocore Holdings plc (the "Company") held its 2024 Annual General Meeting of Shareholders (the "AGM"). The shareholders considered the eleven resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 12, 2024 (the "Proxy Statement"). Set forth below are the results, including the number of votes cast for, against (or, in the case of Resolution 4, "One Year," "Two Years" and "Three Years") and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution. Ordinary Resolutions Resolution 1 : To re-appoint as a director of the Company Bahija Jallal, Ph.D. The votes were cast as follows: For Against Abstain 34,240,387 15,133 4,239 Resolution 2 : To re-appoint as a director of the Company Professor Sir John Bell. The votes were cast as follows: For Against Abstain 30,134,392 4,121,144 4,223 Resolution 3 : To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 33,617,866 636,901 4,992 Resolution 4 : To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. The votes were cast as follows: One Year Two Years Three Years 34,206,579 763 52,417 Based on the results of the vote, and consistent with the recommendation of the Company's board of directors, the Company has determined to hold future non-binding advisory votes to approve the compensation of its named executive officer
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: May 23, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer